Annual report pursuant to Section 13 and 15(d)

Stock-Based Compensation, Restricted Stock and Stock Options (Tables)

v3.20.2
Stock-Based Compensation, Restricted Stock and Stock Options (Tables)
12 Months Ended
Mar. 31, 2020
Share-based Payment Arrangement [Abstract]  
Schedule of stock based compensation expenses

    Years ended March 31,  
    2020     2019  
Research and development expenses   $ 1,759,725     $ 476,948  
Selling, general and administrative expenses     3,355,964       537,742  
Total stock-based compensation   $ 5,115,689     $ 1,014,690  
Schedule of restricted stock awards

    Number of Shares    

Weighted Average
Grant-Date
Fair Value

 
Unvested at March 31, 2018     234,453     $ 0.01  
Vested     (234,453 )   $ 0.01  
Unvested at March 31, 2019     -     $ -  
Granted     6,000,000     $ 0.82  
Vested     (2,249,991 )   $ 0.82  
Unvested at March 31, 2020     3,750,009     $ 0.82  
Schedule of of stock options granted

    Year Ended March 31,
2019
 
Dividend yield     0 %
Expected price volatility     50.0 %
Risk free interest rate     2.58 %
Expected term     5-6 years  
Schedule of stock options

    Shares Underlying Options     Weighted Average Exercise Price     Weighted Average Remaining Contractual
 Term
(Years)
    Aggregate Intrinsic Value  
Outstanding at March 31, 2018     3,578,500     $ 0.05       9.9     $ 1,252,475  
     Granted     2,235,000     $ 0.39       9.8     $ -  
Outstanding at March 31, 2019     5,813,500     $ 0.18       9.2     $ 3,720,395  
Outstanding at March 31, 2020     5,813,500     $ 0.18       8.2     $ 4,243,610  
Exercisable at March 31, 2020     3,467,561     $ 0.20       8.2     $ 2,471,650